BPC June 27 update

Potential biotech stock events for the upcoming week; Biotech week in review

Weekly watchlist

Only two trading days remain in the second quarter of 2020, yet a number of clinical trial readouts slated for release have yet to be announced. It is not uncommon for companies to miss their guided timelines by a few days, and with COVID-19 potentially adding to the delays, it would not be surprising if some of the events listed below slip into early July. Let us see which companies reach their deadlines over the first two trading days of the week.

First, let’s review the week that was with notable healthcare news.


Vaxart, Inc. (NASDAQ: VXRT) shares surged to close the week up 209% to $8.04. The company put out a couple press releases, which garnered interest in the stock, aided by the recent increase in COVID-19 cases in the U.S. Of note, the company announced that its COVID-19 vaccine has been selected to participate in a non-human primate (NHP) challenge study, organized and funded by Operation Warp Speed, a new national program aiming to provide substantial quantities of vaccine by January 2021. Unlike most other vaccines, Vaxart is developing a vaccine tablet instead of a needle injection. Shares of the company have increased by approximately 2500% over the past six months.


Chiasma, Inc. (NASDAQ:CHMA) announced the FDA approved Mycapssa for long-term maintenance treatment in acromegaly patients. Shares, however, sold off on the news, closing Friday down 7% to $6.08.

Zogenix, Inc. (NASDAQ:ZGNX) announced late-Thursday that the FDA approved Fintepla for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older. Shares also sold off on the news, closing down 9% to $25.47.


Translate Bio (NASDAQ:TBIO) shares closed the week up 27% to $19.48 on news it has expanded their existing collaboration and license agreement with Sanofi to develop mRNA vaccines for infectious diseases. Translate Bio will receive a total upfront payment of $425m, consisting of a $300m cash payment and a private placement common stock investment of $125m at $25.59 per share. The company also announced an equity offering raising $125m, which saw shares pull back late in the week.

uniQure N.V. (NASDAQ:QURE) announced a license agreement with CSL Behring for rights to etranacogene dezaparvovec, its gene therapy for patients with hemophilia B. uniQure will receive a $450m upfront payment and is eligible to receive up to $1.6b in milestone payments. However, shares fell sharply Thursday, closing down 22% to $49.22 as hopes diminished of a buyout of the company.


Myovant Sciences (NYSE: MYOV) shares closed Tuesday up 14% to $19.90 on news its second Phase 3 trial of once-daily relugolix combination therapy in women with pain associated with endometriosis, met the co-primary efficacy endpoints and all seven key secondary endpoints.

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) shares fell Tuesday by 43% to $0.35 following its announcement that it will not advance its current Phase 1/2 trial of vecabrutinib for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL) into the planned Phase 2 portion due to lack of efficacy.

Millendo Therapeutics, Inc. (Nasdaq: MLND) also announced that it will not continue development of nevanimibe in patients with congenital adrenal hyperplasia. The decision was made following an interim review of Phase 2b data. Shares closed Tuesday down 17% to $1.99.

Potential biotech stock events for the upcoming week:

Drug Stage Catalyst Market Cap

AKRO – Akero Therapeutics Inc.
Nonalcoholic steatohepatitis (NASH)

Phase 2a Phase 2a dose groups all met primary endpoint - March 31, 2020. Further data released June 30, 2020 noted 48% of patients achieved at least a one-stage improvement in fibrosis without worsening of NAFLD activity score (NAS) and 28% achieved at least a two-stage improvement in fibrosis.
$946.8 million

INCY – Incyte Corporation
Baricitinib (NIAID Adaptive Treatment Trial)
COVID-19 Coronavirus

Phase 3 Phase 3 data due June 2020. (Entry moved to July 2020 due to missed timeline).
$23.1 billion

INO – Inovio Pharmaceuticals Inc.
Coronavirus COVID-19 vaccine

Phase 1 Phase 1 interim data released June 30, 2020. 94% of Phase 1 trial participants demonstrated overall immune responses at Week 6 but no data on how many patients produced antibodies. Phase 2/3 trial to commence July/August 2020.
$3.4 billion

ITRM – Iterum Therapeutics plc
Uncomplicated urinary tract infections (uUTI)

Phase 3 Phase 3 data released June 29, 2020. One of two primary endpoints met.
$21.2 million

LLY – Eli Lilly and Company

Phase 2 Phase 2 data due June 2020. (Entry moved to July 2020 due to missed timeline).
$156.7 billion

OBSV – ObsEva SA
Linzagolix OBE2109 - PRIMROSE 1
Uterine fibroids

Phase 3 Phase 3 data due July 6, 2020.
$274.2 million

REGN – Regeneron Pharmaceuticals Inc.
Kevzara (Sarilumab)
Coronavirus COVID-19

Phase 3 Phase 3 trial did not meet primary endpoint - July 2, 2020.
$63.9 billion

RVNC – Revance Therapeutics Inc.
DAXI (RT002)
Lateral Canthal (Crow’s Feet) Lines

Phase 2 Phase 2 top-line data released June 30, 2020. 88% of subjects achieved a score of none or mild wrinkle or line severity at Week 4 in at least one treatment group.
$1.4 billion

RVNC – Revance Therapeutics Inc.
DAXI (RT002)
Forehead lines

Phase 2 Phase 2 data noted 100% of subjects achieved a score of none or mild wrinkle or line severity at Week 4 in at least one treatment group - June 30, 2020.
$1.4 billion

ZYNE – Zynerba Pharmaceuticals Inc.
Zygel ZYN002
Fragile X syndrome

Phase 2/3 Phase 2/3 trial did not meet primary endpoint - June 30, 2020.
$87.3 million